Gradientech ^Peer

Gradientech is a biotechnology company based in Uppsala, Sweden, founded in 2009. The company specializes in advanced diagnostic solutions for infectious diseases, particularly focusing on antibiotic resistance and sepsis. Gradientech develops microscale tools and microfluidic platforms that enhance live cell imaging and antibiotic susceptibility testing (AST).

One of their key products is QuickMIC®, an ultra-rapid AST system that provides minimum inhibitory concentration (MIC) values from positive blood cultures in just 2–4 hours. This allows for quicker treatment decisions for sepsis patients. Gradientech also offers a patented microfluidic platform that creates controllable chemical gradients for high-resolution live cell analysis, supporting research in chemotaxis and antimicrobial resistance. The company has established a strategic partnership with Hardy Diagnostics to expand its presence in the U.S. and Canadian markets, backed by a significant investment.